BioSpace News Archive

Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that the Company will release its first quarter 2023 financial results on Thursday, May 4, 2023, after the close of U.S. markets.

PTC Therapeutics, Inc. announced a corporate update and financial results for the first quarter ending March 31, 2023.

Amgen announced financial results for the first quarter of 2023.

argenx, a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, announced that it will host a conference call and audio webcast on Thursday, May 4, 2023 at 2:30 pm CET to discuss its first quarter 2023 financial results and provide a business update.

Burning Rock Biotech Limited, a company focused on the application of next generation sequencing technology in the field of precision oncology, announced that it plans to release its unaudited financial results for the first quarter of 2023 before the U.S. market opens on May 30, 2023.

Santhera Pharmaceuticals announces the Company’s preliminary unaudited financial results for the year ended December 31, 2022, reports on progress with its lead drug candidate vamorolone for the treatment of DMD in the U.S. and Europe, and provides updates on its strategic and financing initiatives.As permitted by SIX Exchange Regulation, the Company will publish the full 2022 Annual Report by the end of May.

We have started 2023 with strong results, delivering double-digit sales growth across our Specialty Care, Vaccines and Consumer Healthcare businesses.

Swedish Orphan Biovitrum AB announced its report for the first quarter of 2023

Exploratory feasibility studies of amorphOX® initiated in collaboration with two international biopharmaceutical and vaccine companies.

Mainz Biomed NV, a molecular genetics diagnostic company specializing in the early detection of cancer, announces the following activities in May.